Kalvista Pharmaceuticals (NASDAQ:KALV) announced its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01), MarketWatch Earnings reports. Kalvista Pharmaceuticals had a negative net margin of 229.45% and a negative return on equity of 31.21%.
Shares of KALV stock opened at $13.99 on Tuesday. The company’s fifty day simple moving average is $12.38 and its 200-day simple moving average is $11.13. Kalvista Pharmaceuticals has a 52 week low of $5.61 and a 52 week high of $18.96. The company has a market cap of $250.46 million, a PE ratio of -8.53 and a beta of 2.44.
Several equities analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 17th. ValuEngine downgraded shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 1st. HC Wainwright reissued a “buy” rating on shares of Kalvista Pharmaceuticals in a research note on Thursday, July 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Kalvista Pharmaceuticals in a research note on Wednesday, July 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $22.67.
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Article: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.